Depression
Student Name
Institutional Affiliation
Course
Instructor
Date
Depression
Question 1.
Depending on the condition and the age limit, the first medication that I would prescribe for madam Angela includes SSRIs such as sertraline and escitalopram. According to (Toth et al., 2019), these are the first-line agents for the initial treatment of moderate depression in adults and are considered safer than other antidepressants as they cause fewer bothersome side effects. The medication may take up to about six weeks for full results before further medication prescription. Also, cognitive behavior therapy (CBT) may be used in some cases as a follow-up to the well-being of the patient.
SSRIs such as sertraline and citalopram are among the first-line medication for moderate depressions, as illustrated earlier. However, in case the patients come back in a couple of weeks with a report of not showing any changes in her mood, further medication may be required. In this case, my response to madam Angela is that she should wait up to the fourth or fifth week as this medication takes up to six weeks for full effect, and she only on her second week. I would also introduce a program for cognitive behavior therapy to remain in tach with her before further medication.
3.
For madam, the medication prescribed might not have any possible problems since she has to follow the appropriate time. At her age, these medications are considered as the first-line agents for the condition. Therefore, as the doctor in charge, I would urge her to have patience and let the SSRl medicines take the appropriate time for full effect before suggesting any other medication type.
4.
Following the right procedures, her treatment should take at least four weeks in her doses. After the four weeks are over, and the patients still show no minimal improvement, I might consider increasing the dose up to the sixth week in expectation of improvement. Nonetheless, the interval duration of antidepressants may take 6 to 9 months after resolving the symptom to prevent relapse and recurrence (Park, & Zarate Jr, 2019).
References
Park, L. T., & Zarate Jr, C. A. (2019). Depression in the primary care setting. New England Journal of Medicine, 380(6), 559-568.
Toth, B., Hegyi, P., Lantos, T., Szakacs, Z., Karimi, B., Varga, G., … & Rakonczay, Z. (2019). The efficacy of saffron in the treatment of mild to moderate depression: a meta-analysis. Planta Medica, 85(01), 24-31.